Very excited to present our phase 2 RCT on “ autologous macrophage therapy for liver cirrhosis” published today in @NatureMedicine https://t.co/uetgfK8i8p ⚡️I've summarised some of the key aspects of the trial 🧵

Brilliant expert panel discussed hosted by Prof. Matt Armstrong and Prof. Suzanne Norris .. a vibrant discussion emphasising the importance of an MDT approach with emphasis on AHP involvement and lifestyle intervention @Drfattyliver @BASLedu #BASL2025

Superb lecture by @brennap9 for the prestigious #SheilaSherlock award… Adding to the illustrious winners - @Drwenhaoli @KushAbey @prakramacha @FSampaziotis @Drfattyliver & many other legends….

Huge body of work! Big fan 🤩 congratulations @brennap9 👍

A very worthy Sheila Sherlock winner - congratulations ⁦@brennap9⁩ #basl2025 ⁦@BASLedu⁩ ⁦@JVLazarus⁩ ⁦@aelsharkawy75⁩ ⁦@Drwenhaoli⁩ ⁦@druppygill⁩ ⁦@tom_marjot⁩ ⁦@DebbieShawcros1⁩ ⁦@stumcp⁩ ⁦@BritSocGastro⁩

@OTavabie @brennap9 @BASLedu @JVLazarus @aelsharkawy75 @Drwenhaoli @druppygill @tom_marjot @DebbieShawcros1 @stumcp @BritSocGastro Well deserved indeed! Excellent researcher and colleague. They are lucky to have him!

This is a MUST read - lots of practical tips and insights relevant to anyone managing patients with liver disease @BASLedu @BSGTrainees @BavenoCoop @EASLedu @AASLDtweets @WAGE_media @ScotSocGastro @ulstergastro @LiverTrust

Superb surgical team (& not bad medical colleagues 😉). And most importantly a great chance to help our liver patients awaiting a life saving liver transplant

This was a really enjoyable #MASLD meeting with @basl_events It's always great to have basic science, translational research, and clinical updates placed side-by-side 🙏Thanks to @AHadjihambi @TessCacciottolo @JAFallowfield @brennap9 @WillAlazawi @barbarat1966 @leannehodgson4

Amazing stuff - moving to prospectively collected data demonstrates the evolution of @uk_torch - good luck with this project which is patient-centric and an area of need! An RCT for the next one maybe @RajivJalan1 @BASLedu @BritSocGastro @UK_CLIF @BSGTrainees

📢 Just announced! The next BSG/FG webinar "Decompensated Cirrhosis – Bundles and Beyond" is happening on 🗓️ 1st October ⏰ 19:00–20:00 BST Join hepatology heavyweights @ebtapper, @salvatore_piano & @stumcp for what promises to be a top-tier session, hosted by 🎙️ @KGananandan,

📢 We are about to GO LIVE with our next project EVADE 📢 Evaluation of the Variation in Management and Outcomes after an Acute Decompensation of Liver cirrhosis Event From speaking to patients we know this is an area of unmet need! #livertwitter 🦋 https://t.co/HbRTEhmZlk

Delighted to share our work on behalf of @BritSocGastro Quality Standards group in collaboration with the @LiverTrust 'Development and feasibility of a patient-reported experience survey for outpatients with liver disease' in @FrontGastro_BMJ https://t.co/otZLTp9ta0

🩺 Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease linked to obesity, diabetes, and metabolic syndrome. In this practical Q&A, Dr Paul Brennan @brennap9 shares how to: 🔹Recognize key risk factors 🔹Use non-invasive tools for early

🚨 Big news! We're thrilled to announce that Frontline Gastroenterology @FrontGastro_BMJ is now the official journal partner of the Roux Group @roux_group – the trainee arm of AUGIS @AUGISnews! Editor-in-Chief Dr Philip Smith @PhilSmithIsBack: “Surgeons are key to the MDT in GI,

https://t.co/y8IPMV2ODB 📣📣📣 Calling all @BSGTrainees @BSGNurses @BASLedu #GITwitter #livertwitter Registration is now open for the BSG Introduction to Research Day for Trainees & Nurses 29th Nov 2025 Radisson Hotel York Register now! @OTavabie @tom_marjot @RCPhysicians

Such an important initiative 👏🏻 Liver disease is silent until advanced stages when symptoms start to show. Screening allows for early detection and intervention, aiming to prevent cirrhosis and liver cancer 💚 @HSELive @IrishHaemAssoc @PBCIreland @AlcoholIreland

@DrLoomba @AlkhouriNaim @TheLancet @JVLazarus @Drfattyliver @EASLnews @JAFallowfield @ProfJohnDillon @dundeeuni @OTavabie @LancetGastroHep @BASLedu @UCSDHealth Read the full paper here; the future of advanced liver-directed therapies is getting ever closer. https://t.co/89Aj3nvKTs More treatments offer better outcomes for patients, particularly as we begin to understand differences in phenotypes and outcomes in patients with MASLD.

Our commentary of the very novel anti-sense oligonucleotide trial in MASH by @DrLoomba and @AlkhouriNaim in @TheLancet https://t.co/7RqZxvDANx Another future tool? Let's hope so, the field is moving at pace on the back of EMEA approval of #rezdiffa and FDA of #Sema

Amazing achievement @novonordisk @phil_newsome7 @unibirmingham @BirminghamBRC @uhbtrust 16 years! on from the start of our phase 2 LEAN (liraglutide) RCT @TheLancet. Drug development is difficult in #NASH, even when GLPs were approved for other conditions it’s taken this long

🔝🔝🔝 FDA grants accelerated approval to Wegovy (semaglutide 2.4 mg injection) for treating adults with non‑cirrhotic metabolic dysfunction‑associated steatohepatitis (MASH) with moderate to advanced fibrosis (but not with cirrhosis). https://t.co/nRzDIR82C3